National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Ixabepilone added to Uterine Neoplasms Guideline; Cervical Cancer Guideline Also Updated

The NCCN Clinical Practice Guidelines in Oncology™ for Uterine Neoplasms have been updated to v.1.2010. For patients with recurrent, metastatic, or high-risk endometrial carcinoma, systemic therapy with ixabepilone as a single agent was added as a second line option. This recommendation is listed as Category 2B.

The NCCN Clinical Practice Guidelines in Oncology™ for Cervical Cancer have also been updated and published by NCCN as v.1.2010.